Increased CASP6 (Halawani et al., 2010; L. Zhou et al., 2019) and decreased Trx1 levels (Lovell et al., 2000; Raffel et al., 2003; Venojarvi et al., 2014) are well‐established hallmarks of AD, indicating the relevance of our findings to pathophysiology of the disease. This evidence concerns the gene CASP6 and Alzheimer disease.